纤维素保护的金纳米集群作为一种有效的抗凝剂
Jinfeng Quan1, Wenyu Sun1, Liu Liu1
1State Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing 211189, PR China.
Journal of colloid and interface science
|May 8, 2025
概括
新的黄金纳米集群 (FIB-AuNCs) 显示出作为抗凝剂的前景. 这些超小集群有效地抑制了血栓激素活性,提供了降低毒性的氨酸更安全的替代品.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 血液学 血液学 血液学
背景情况:
- 血 (TB) 是纤维素原 (FIB) 转化和血栓形成的核心.
- 当前的抗凝血剂,如氨酸,具有局限性和副作用.
- 需要新的抗凝策略来提高患者的安全性和疗效.
研究的目的:
- 研究基于纤维素原模板的黄金纳米集群 (FIB-AuNCs) 作为新型抗凝剂的潜力.
- 为了比较FIB-AuNCs与传统抗凝剂 (如肝素) 的疗效和安全性.
主要方法:
- 合成基于纤维素原模板的黄金纳米集群 (FIB-AuNCs).
- 评估FIB-AuNCs在体外抑制血栓激素活性的能力.
- 在体内模型中对抗凝血剂有效性和毒性的评估.
- 与较大的金纳米颗粒和肝素进行比较.
主要成果:
- 通过保留FIB-TB结合部位,FIB-AuNCs直接和有效地抑制血栓活性.
- 与较大的金纳米颗粒相比,超小的FIB-AuNCs显示出更高的抗凝剂疗效.
- 在体外和体内研究证实了FIB-AuNCs的高疗效和安全性,肝脏和脏毒性相比降低了heparin.
结论:
- 基于纤维素原模板的金纳米集群 (FIB-AuNCs) 是一种有前途的新型抗凝剂.
- FIB-AuNCs的超小尺寸提高了疗效,降低了毒性.
- FIB-AuNCs具有临床应用和先进抗凝固疗法开发的潜力.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
546
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
546
01:16Clot Retraction and Fibrinolysis
2.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
2.8K